AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06338826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir (rDVR)
Description: dual therapy without TDF or TAF but including 3TC in combination with Dolutegravir (DTG) or ritonavir-boosted Darunavir (rDVR
Study NCT04489719 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT04489719 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04489719 — intervention group
Intervention type: DRUG
Intervention: Radium Ra 223 Dichloride
Description: Given IV
Study NCT06371807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab injection
Description: (KXCb - PA\[E\]C) vs (KPA\[E\]C - KXCb) Pembrolizumab (K) + paclitaxel (X) + carboplatin (Cb) followed by pembrolizumab + doxorubicin or epirubicin (A or E) + cyclophosphamide (C) followed by pembrolizumab in the adjuvant setting vs Pembrolizumab + doxorubicin or epirubicin (A or E) + cyclophosphamide (C) followed by pembrolizumab (K) + paclitaxel (X) + carboplatin (Cb) followed by pembrolizumab in the adjuvant setting
Study NCT06371807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab injection
Description: (KXCb - PA\[E\]C) vs (KPA\[E\]C - KXCb) Pembrolizumab (K) + paclitaxel (X) + carboplatin (Cb) followed by pembrolizumab + doxorubicin or epirubicin (A or E) + cyclophosphamide (C) followed by pembrolizumab in the adjuvant setting vs Pembrolizumab + doxorubicin or epirubicin (A or E) + cyclophosphamide (C) followed by pembrolizumab (K) + paclitaxel (X) + carboplatin (Cb) followed by pembrolizumab in the adjuvant setting
Study NCT06683703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone combined with Bevacizumab
Description: In the combination group, the dose of Utidelone was determined according to the safety run-in period, 30 mg/m2/d or 25mg/m2/d, D1-D5,Q3W; The dose of Bevacizumab was 15 mg/kg/3W.
Study NCT06683703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone combined with Bevacizumab
Description: The dose of Utidelone was 30 mg/m2/d or 25mg/m2/d, D1-D5,Q3W; The dose of Bevacizumab was 15 mg/kg/3w.
Study NCT06684873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112 Injection
Description: AK112 injection plus chemotherapy was administered to all eligible patients
Study NCT06684444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: firefighter Sleep Health Coaching Intervention (ffSHC)
Description: This multi-component intervention is based on principles of cognitive behavioral therapy for insomnia. It includes telephone-based sleep health coaching to individuals, targeted training and sleep health education to fire service leaders, agency-level sleep health promotion, and facilitation strategies to internal facilitators.
Study NCT06684444 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control (Minimally Enhanced Usual Care)
Description: The control arm is minimally enhanced usual care. Usual care interventions for sleep disturbance include any health or wellness interventions administered by the agency on the topic of sleep, including occupational health intervention, employee assistance programs, education, signage, and webinars. The type and dose of care will be assessed at each timepoint. Minimal enhancement is a referral to the agency's Employee Assistance Program and will address the ethical problem in the control condition of identifying but not treating a sleep disturbance.
Study NCT06684717 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational video intervention
Description: A 3-minute educational video mainly about the benefits of Continuous positive airway pressure therapy in OSA patients. The video starts with basic knowledge about OSA and how it affects human health. What is a CPAP machine and how does it works? It was developed from consensus among expert opinions of Neurobehavioral specialists and sleep physicians.
Study NCT05381870 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Test Preparation-Reference preparation
Description: Under fasting conditions, subjects randomly divided into TR group were given one tablet of test preparation first, and then one tablet of reference preparation after cleaning period.
Study NCT06683118 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapamycin neurovascular Balloon Catheter
Description: Drug-coated balloon for the symptomatic cerebral atherosclerotic stenosis
Study NCT06683118 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Balloon
Description: Conventional Balloon for the symptomatic cerebral atherosclerotic stenosis
Study NCT05164367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine sulfate gel (0.01%)
Description: A research nurse will measure 1 gram of gel using a calibrated measuring spoon and will provide it to the participant for self-administration.
Study NCT05982314 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gamma-PN3
Description: Experimental whole-cell pneumococcal vaccine
Study NCT06683950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept 8mg
Description: Switching to intravitreal aflibercept 8mg in patients previously treated with faricimab or aflibercept 2mg.~The dosing schedule is as follows.~1. A single dose of 8mg aflibercept was administered to all patients~2. After treatment 1, follow-up observations were conducted at the same intervals as previous treatments. If complete fluid resolution (no evidence of SRF or IRF) is observed, an additional dose of 8mg aflibercept is administered, extending the dosing intervals by two weeks each time.~3. Up to three doses of 8mg aflibercept can be administered.~4. If, after the administration of 8mg aflibercept, follow-up observations reveal remaining SRF or IRF, the study concludes without additional dosing.
Study NCT06682156 — intervention group
Intervention type: DRUG
Intervention: Carfilzomib
Description: carfilzomib C1: 20mg/m2，D1-2; 27mg/m2，D8-9; 36mg/m2，D15-16 C2 and subsequent cycles: 36mg/m2。
Study NCT06686433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel infant formula
Description: Infants are fed with the novel infant formula from the date of enrollment to the age of 6 months.
Study NCT06686433 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard infant formula
Description: Infants are fed with the standard infant formula from the date of enrollment to the age of 6 months.
Study NCT06708026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action Observation and Motor Imagery (AOMI) training
Description: Participants will watch home-based exercise videos and simultaneously imagine themselves performing these exercises in their minds by following verbal instructions in the videos, without actual execution.
Study NCT05370157 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TeamTRACS
Description: TeamTRACS is a team training intervention adapted from TeamSTEPPS (Team Strategies and Tools to Enhance Performance and Patient Safety), a widely used evidence-based team training developed by the Agency for Healthcare Research and Quality. TeamTRACS targets knowledge, skills, and attitudes related to team member roles, shared awareness, communication, mutual support, and goal-setting. TeamTRACS is structured, easy to use, flexible in length and intensity, and requires few resources. It incorporates didactic instruction, discussion, and interactive activities and can be delivered virtually or in-person.
Study NCT05982314 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumovax-23
Description: Licensed pneumococcal vaccine
Study NCT06708026 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic wheelchair exercises
Description: A set of low-intensity warm-up wheelchair exercises developed specifically for survivors with spinal cord injury
Study NCT06708026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic wheelchair exercises
Description: A set of low-intensity warm-up wheelchair exercises developed specifically for survivors with spinal cord injury
Study NCT06708026 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Watch landscape videos
Description: A set of landscape videos
Study NCT06729983 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylactic Conjoint Tendon Lengthening
Description: During a standard reverse shoulder arthroplasty procedure, the conjoint tendon will be incised and lengthened prophylactically
Study NCT06729983 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Reverse Shoulder Arthroplasty
Description: A standard reverse shoulder arthroplasty procedure will be performed
Study NCT06744257 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Education tool
Description: An online education tool that contains 4 modules
Study NCT06748183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Power Training
Description: Group A will participate in Functional Power Training (FPT) alongside routine physical therapy The exercise protocol aims to enhance strength, mobility, and endurance through resistance training across various functional activities. It includes exercises such as running, walking, chair pushing, stair climbing, propelling a stable scooter, and sideways walking, all performed at 50-70% of the participant's maximum speed. Resistance is added using methods like dragging a loaded box with a belt during running and walking, pushing a chair with a loaded box underneath, wearing a loaded vest while climbing stairs, and attaching a loaded box to a scooter for propulsion exercises. Each exercise involves 6 to 8 repetitions lasting 25 seconds, followed by 30 to 50 seconds of rest. This structured regimen focuses on controlled movement and endurance, providing a comprehensive approach to improving physical performance.
Study NCT06748183 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine physical therapy
Description: Routine physical therapy for a child with Cerebral Palsy involves hot pack for muscle relaxation and isometric exercises to enhance motor skills, muscle strength, and coordination. Passive stretching will be given as a treatment plan. Therapists employ sit to stand exercise to improve gait, posture, and overall functional abilities. Regular progress evaluations are conducted to adjust interventions, ensuring ongoing improvements.
Study NCT05592938 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: rPBI
Description: External beam partial breast reirradiation (rPBI) using 26Gy in 5 fractions delivered daily over 1-week
Study NCT06758557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0025
Description: HB0025 IV every 3 weeks (q3w)
Study NCT06758557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m² iv d1
Study NCT05990335 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mHealth application (custom)
Description: Smartphone based application designed to engage user executive functions
Study NCT05381870 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reference preparation-Test Preparation
Description: Under fasting conditions, subjects randomly divided into RT group were given one tablet of reference preparation first, and then one tablet of test preparation after cleaning period.
Study NCT05957523 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning
Description: The participants rested in the supine position for 5 minutes, then turn on the ischaemic preconditioning apparatus and place the automatically programmed blood pressure cuff on both upper arms of the participant, pressurize to 200 mmHg, pressurize for 5 minutes, rest for 5 minutes, perform 4 cycles for a total of 40 minutes each time. The training for participants in group A will be performed once daily, while for participants in group B the training will be performed twice daily. And heart rate and blood pressure before and after each training will be recorded for 7 days.
Study NCT05982314 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar-13
Description: Licensed pneumococcal vaccine
Study NCT05982314 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline placebo
Study NCT05990335 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth application (custom)
Description: Smartphone based application designed to engage user executive functions
Study NCT04060108 — intervention group
Intervention type: DRUG
Intervention: MDMA
Description: 80mg, 120mg, Placebo
Study NCT05148299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Description: 20-cc glass vials-1080 mg
Study NCT06041971 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AIDANET system
Description: The study will involve testing a new AID system designed to enable full closed loop control and consisting of the following elements: the diabetes assistant (DiAs) prototyping platform (MAF 2019), connected to a Tandem t:AP research insulin pump and a Dexcom G6 CGM, and implementing the University of Virginia (UVA) AIDANET algorithm.
Study NCT05100095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Hypofractionated radiation therapy to the primary tumor and/or lymph nodes
Study NCT06296537 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Neuromuscular Stabilization Training (DNS)
Description: Dynamic neuromuscular stabilization training has been developed, which optimizes the movement system based on the scientific principles of developmental kinesiology. DNS training aims to stimulate the natural movement control system in the brain to activate the body's stabilization system. Supine, prone, oblique sitting, tripod, high kneeling, hanging stance-midstance faze, hanging stance- propulsion, bear, squat exercises will be applied.
Study NCT06296537 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: Multi-plane single limb challenges, jumping and landing exercises, proprioceptive exercises, and perturbation exercises
Study NCT06296537 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Training
Description: Education, electrotherapy, soft tissue fascia massage, stretching, range of motion, strengthening and postural control exercises
Study NCT06124690 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: Pulmonary vein isolation and ablation of low voltage areas.
Study NCT06326463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40mg/m2, Day -4, -3 and -2
Study NCT06326463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Day -3 and Day-2~REST DAY, -1
Study NCT06326463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD70-CAR T cell infusion (Autologous)
Description: Day 0 or +1
Study NCT06326463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mesna is generally dosed at approximately 25% of the cyclophosphamide dose. It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide
Study NCT06694584 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tea(m)Time
Description: Tea(m)Time is divided into two phases, starting with the qualification of team leaders. This starts with knowledge transfer about healthy leadership, resilience, occupational health and safety, posture work, psychological empowerment, agile management and the role of the manager. The team leaders also learn various moderation/coaching techniques. The qualification is followed by the implementation of Tea(m)Time. The teams start each hour with self-reflection. This is followed by a stress assessment and prioritization. The teams then work on the problems identified and look for solutions together.
Study NCT06688786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant mFOLFOX6 chemotherapy combined with PD-1 inhibitor therapy
Description: Preoperative treatment with 4-6 cycles of mFOLFOX6 regimen combined with serplulimab
Study NCT03909685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Mental Health App
Description: The Mobile Mental Health App is an app that utilizes artificial intelligence to identify symptoms and provides targeted, tailored solutions for its users.
Study NCT05286229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-383
Description: Intravenous (IV) Infusion
Study NCT06758557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m² iv d1
Study NCT06758557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 iv d1
Study NCT06295926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: Undergo 4 cycles of synchronous radiotherapy and chemotherapy combined with Sintilimab immunotherapy, followed by Sintilimab monotherapy for maintenance treatment until disease progression or up to 1 year.
Study NCT06637540 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RescueDoppler
Description: Continous handsfree pulsed wave Doppler of the common carotid artery during cardiac surgery
Study NCT06637540 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RescueDoppler
Description: Continuous hands-free Doppler ultrasound of the common carotid artery during cardiac surgery
Study NCT04866472 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: video-laryngoscope and GlideRite Rigid Stylet
Description: Once subject is in the operating room, standard monitoring will be instituted including nerve stimulator. Induction will follow standard practice.Once full muscle relaxation is confirmed with a train of four of 0/4 laryngoscopy will be preformed using a video-laryngoscope (VLS) with a #3 blade for women and a #4 blade men. Endotracheal intubation will be performed using a #7 endotracheal tube in women and # 8 in men using the GlideRite Rigid Stylet. The stylet will be shaped to the curvature of the blade of the VLS and lubricated with a water-based lubricant. After successful tracheal intubation the circuit will be connected and ventilation confirmed with capnography and auscultation.
Study NCT04866472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: video-laryngoscope and TCI Articulating Introducer Device
Description: In the operating room, standard monitoring will be instituted including nerve simulator. Induction will follow standard practice. Once full muscle relaxation is achieved (train of four of 0/4) laryngoscopy will be performed using a video-laryngoscope (VLS) using a #3 blade in women and a #4 blade in men. A #7 endotracheal tube will be used for women and a #8 for men. Endotracheal intubation will be performed by placing the tube on the back of the TCI articulating introducer, after shaft is lubricated with a water based lubricant. The tip of the TCI articulating introducer will be maneuvered into the trachea and advanced until the green zone of the introducer shaft is adjacent to the glottis. The handle of the articulating introducer will then be removed and the ETT will be advanced over the articulating introducer and into the trachea via Seldinger's technique. Once in place the respiratory circuit will be connected and confirmed with capnography and auscultation.
Study NCT05187481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jianpi Huatan dispensing granule
Description: once a day in the morning and evening, 30 days as a course of treatment, a total of 3 courses.
Study NCT05187481 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo granule
Description: once a day in the morning and evening, 30 days as a course of treatment, a total of 3 courses.
Study NCT06769477 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Experimental Group
Description: individuals will receive diabetes education with motivational interviewing technique based on health belief model
Study NCT05468320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caplacizumab
Description: Lyophilized powder for solution for injection.
Study NCT05468320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Solution for injection or Tablet
Study NCT05468320 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD20 antibody
Description: Solution for injection
Study NCT06777433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD101 (18F-FPIA)
Description: A single dose of 18F-RAD101 with a maximum of 370 MBq (10 mCi) administered as a slow IV bolus injection over a maximum of 30 seconds, followed by a saline flush.
Study NCT06768190 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: WhatsApp as usual
Description: Pregnant women and their partners are instructed to use WhatsApp as normal for six weeks.
Study NCT06768190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WhatsApp-based psycho-socio-educational intervention (WeLove)
Description: The intervention comprises six sessions, including psychoeducation, communication training, sleep hygiene, stimulus control, cognitive restructuring, and behavioural activation. Each session has two short videos, quizzes, forums, and homework. The content is presented through a virtual midwife using storytelling of real-life scenarios, animation, and case vignettes about psychological and sleep problems during pregnancy. A virtual midwife acts as an educator to explain the prevalence, causes, and factors of psychological and sleep problems. Every session will concentrate on certain courses and offer specialised advice to expectant mothers and their partners. Using the security links on the WhatsApp platform, each session takes 15 to 20 minutes to finish.